Please login to the form below
heart attack patients
This page shows the latest heart attack patients news and features for those working in and with pharma, biotech and healthcare.
Novartis withdraws EU filing for canakinumab
The company has completed a phase 3 study of canakinumab as a treatment to prevent stroke and myocardial infarction (MI) or death in patients who have already suffered a heart attack - ... This showed that injections of canakinumab every three months
Latest news
-
NHS could save £7bn with greater diagnostics use
It’s important for all stakeholders that we take every opportunity to rapidly adopt tests which show cost savings and benefit to patients.". ... It found that using the high sensitivity cardiac troponin test to diagnose or rule out heart attack in
-
Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?
Amgen’s FOURIER reduced heart attack risks by 27%, stroke risks by 21% and coronary revascularisations by 22%, but didn't provide a mortality benefit. ... Herceptin, which could reduce their risk of heart damage while making significant cost-savings
-
CV data sets up Novartis' Ilaris for blockbuster sales
with a prior heart attack and inflammatory atherosclerosis when added to standard therapy. ... Novartis' chief medical officer Vas Narasimhan is hopeful. "Despite current treatment, about 25% of heart attack survivors will have another cardiovascular
-
New outcomes data could unlock Repatha's potential, says Amgen
In the four-year FOURIER trial - which involved 27, 500 patients - the drug significantly reduced the risk of heart attack, stroke and death in patients with heart disease in patients with ... The findings back up an earlier, smaller study ( GLAGOV),
-
Novartis boosts cardiovascular pipeline with $1bn Ionis deal
The agreement covers drugs designed to reduce two well-characterised factors - lipoprotein(a) and apolipoprotein CIII - that elevate the risk of serious complications such as heart attack and stroke in patients ... Aside from the new additions, Novartis
More from news
Approximately 1 fully matching, plus 50 partially matching documents found.
Latest Intelligence
-
Proving real-world value
Insights reach R&D that ordinarily take years; beta-blockers, for example, found expanded use to control hypertension only after retrospective analysis of four decades of use in heart attack patients.”. ... We create thousands of patient leaflets
-
Patient collaborations
Published: 21 Nov 2011. AZ’s patient support programme provided holistic support to newly diagnosed heart attack patients. ... Improve discharge information. Maximise adherence to medication. Address psychological health. AstraZeneca also launched a
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Understanding the "Big Picture"
In this case, of the male patients with ACS, 27% experienced angina and 73% experienced a heart attack. ... This quickly demonstrates that the majority of male patients who experience a heart attack will be found within the non ST-elevated heart attack
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Account Manager
-
Competitive Salary Offered
-
Associate Director
-
£75, 000-90, 000
-
Account Director
-
Competitive Salary Offered
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Manager / Account Director
-
Competative
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Global Business Development Director – Health Education
-
excellent commission
-
Medical Writer
-
Salary TBC
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Business Director
-
Competitive Salary Offered
Subscribe to our email news alerts
- China’s clinical trial shake-up
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
PMHub
AMICULUM Limited
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...
Latest intelligence
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
Quick links
Infographics
